Biotech Values

[Titan V]

Opdivo still clear immunotherapy leader despite Keytruda gains
http://pharmaphorum.com/news/opdivo-still-leader-keytruda-gains/

...But while Merck has all the momentum behind it, BMS’ Opdivo is very much the market leader in terms of revenues – at least for now.

While Keytruda reached sales of $1.40 billion for 2016, Opdivo was way out ahead with revenues of $3.77 billion. Keytruda is expected to overhaul it in the long run, but Opdivo produced excellent growth in Q4, with revenues growing to $1.3bn compared to $475 million the year before.